New advances of adiponectin in regulating obesity and related metabolic syndromes  

作　　者：Yanqi Han Qianwen Sun Wei Chen Yue Gao Jun Ye Yanmin Chen Tingting Wang Lili Gao Yuling Liu Yanfang Yang 

机构地区：[1]State Key Laboratory of Bioactive Substance and Function of Natural Medicines,Institute of Materia Medica,Chinese Academy of Medical Sciences&Peking UnionMedical College,Beijing,100050,China [2]Beijing Key Laboratoryof Drug Delivery Technology and NovelFormulation,Institute of Materia Medica,Chinese Academyof Medical Sciences&Peking UnionMedical College,Beijing,100050,China

出　　处：《Journal of Pharmaceutical Analysis》2024年第5期623-638,共16页药物分析学报（英文版）

基　　金：supported by the grants from the CAMS Innovation Fund for Medical Sciences(CIFMS)(Grant No.:2021-I2M-1-026);the Beijing Natural Science Foundation of China(Grant Nos.:7212155 and 7162135).

摘　　要：Obesity and related metabolic syndromes have been recognized as important disease risks,in which the role of adipokines cannot be ignored.Adiponectin(ADP)is one of the key adipokines with various beneficial effects,including improving glucose and lipid metabolism,enhancing insulin sensitivity,reducing oxidative stress and inflammation,promoting ceramides degradation,and stimulating adipose tissue vascularity.Based on those,it can serve as a positive regulator in many metabolic syndromes,such as type 2 diabetes(T2D),cardiovascular diseases,non-alcoholic fatty liver disease(NAFLD),sarcopenia,neurodegenerative diseases,and certain cancers.Therefore,a promising therapeutic approach for treating various metabolic diseases may involve elevating ADP levels or activating ADP receptors.The modulation of ADP genes,multimerization,and secretion covers the main processes of ADP generation,providing a comprehensive orientation for the development of more appropriate therapeutic strategies.In order to have a deeper understanding of ADP,this paper will provide an all-encompassing review of ADP.

关 键 词：ADIPONECTIN OBESITY Metabolic syndrome REGULATION 

分 类 号：R969.1[医药卫生—药理学]